AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00568451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC=2 intravenously on days 1, 8 and 15. Re-treat every 4 weeks until progression, unacceptable toxicity, or refusal
Study NCT00568451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 100mg/m\^2 intravenously on days 1, 8 and 15. Re-treat every 4 weeks until progression, unacceptable toxicity, or refusal
Study NCT00568451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: 150mg/m\^2 at cycle 1, 200mg/m\^2 at cycle 2 and beyond, orally on days 1-5. Re-treat every 4 weeks until progression, unacceptable toxicity, or refusal. One treatment cycle=four weeks
Study NCT03676608 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bee Wax Mammary Areolae
Description: The product to be valued are mammary areolae made by hand with organic beeswax. Despite its honey aroma, it does not contain honey. The wax used for the manufacture of the areolae is operculum. This wax is used and not another because it avoids possible residues and allergies that may contain other types of waxes. The operculum wax is used as a thickener in pharmacy and cosmetic products as a fat base in ointments and creams.
Study NCT03676608 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual educational care
Description: The WHO protocol for maternal lactation.
Study NCT03676608 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual educational care
Description: The WHO protocol for maternal lactation.
Study NCT01537042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Transdermal patch; Dose: 1 mg/24 h, 2 mg/24 h or 3 mg/24 h once daily depending on optimal dose; maximal dose is 3 mg/24 h.~Subjects start with a Rotigotine dose of 1 mg/24 h for 1 week. The dose can be increased weekly during Up-Titration Period until either the optimal or the maximal dose of 3 mg/24 h has been reached. Subjects will maintain the optimal/maximal dose during the 2-week Maintenance Period. Following the Maintenance Period, subjects will be de-escalated from their optimal dose by decreasing the dose by 1 mg/24 h every other day during Taper Period until complete withdrawal.
Study NCT01537042 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Transdermal patch; Patches matching to active treatment patches in size and appearance.~Up to 3 weeks of Titration,~2 weeks of Maintenance,~Up to 4 days of Taper Period.
Study NCT05330117 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TENS
Description: This device will then be used for deep transcutaneous nerve stimulation at the T10-L1 and S2-S4 levels. The device will be placed and activated 5 minutes before the procedure. and the device will remain active during the procedure and will be turned off as soon as the procedure is complete (procedure typically will take from 5-15 minutes). The TENS units have pre-program settings improving convenience, reproducibility and reliability. Study staff will be instructed to perform TENS using an Acupuncture mode on the provided TENS units. The amplitude will be adjusted to a comfortable sensation that does not cause pain using adhesive electrodes. One TENS unit is able to support 4 TENS electrodes. The TENS electrodes (8 cm x 5 cm) will be placed on bilateral paraspinal muscles. The intensity of the stimulation (Hz) will be adjusted to the subjective comfort of the subject.
Study NCT05330117 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control TENS
Description: This device will then be used for deep transcutaneous nerve stimulation at the T10-L1 and S2-S4 levels. The device will be placed and activated 5 minutes before the procedure. and the device will remain active during the procedure and will be turned off as soon as the procedure is complete (procedure typically will take from 5-15 minutes). The TENS units have pre-program settings improving convenience, reproducibility and reliability. Study staff will be instructed to perform TENS using an Acupuncture mode on the provided TENS units. The amplitude will be adjusted to a comfortable sensation that does not cause pain using adhesive electrodes. One TENS unit is able to support 4 TENS electrodes. The TENS electrodes (8 cm x 5 cm) will be placed on bilateral paraspinal muscles. The intensity of the stimulation (Hz) will be adjusted to the subjective comfort of the subject.
Study NCT01113892 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: vascular grafts
Description: All devices will be used to treat patients with peripheral arterial occlusive disease
Study NCT01113892 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vascular grafts
Description: All devices will be used to treat patients with peripheral arterial occlusive disease
Study NCT04144400 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Direction Check App
Description: Direction Check is a simple, inexpensive app that builds resilience through balanced values to target the everyday personal and occupational stressors faced by military populations.
Study NCT04144400 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Direction Check App (Time Management Version)
Description: Direction Check (Time Management Version) is a simple, inexpensive app that builds resilience through time management exercises to target the everyday personal and occupational stressors faced by military populations.
Study NCT00006411 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: corneas assigned by donor age group
Description: A web-based computer program was used to select and assign a cornea by donor age group from those available at the eye bank that met the study eligibility criteria. The program randomly selected a cornea based on a two-level minimization procedure which attempted first to balance for each surgeon the number of corneas from donors >=66 and \<66 years old and then, when possible, to balance among age subgroups of 10-35, 36-50, 51-65, 66-70, and 71-75 years. The assignment was made without regard to recipient age or any other subject characteristics.
Study NCT02363543 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyalomatrix
Study NCT02363543 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Integra
Study NCT01352572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antidepressant response
Description: Antidepressants administration for 6 weeks under therapeutic dose responders
Study NCT01352572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antidepressant non-response
Description: Antidepressants administration for 6 weeks under therapeutic dose nonresponders
Study NCT03858972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesetaxel
Description: Tesetaxel plus reduced dose of capecitabine
Study NCT03858972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Reduced dose of capecitabine
Study NCT04465669 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orsiro stents
Description: Percutaneous coronary intervention with implantation of either:~a Orsiro® biolimus a9 eluting coronary stent
Study NCT04465669 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resolute Integrity® stents
Description: Percutaneous coronary intervention with implantation of either:~a Resolute Integrity® zotarolimus eluting coronary stent
Study NCT03260556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pirfenidone
Description: Increasing doses
Study NCT03260556 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Increasing doses
Study NCT02768480 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Primary Care
Description: Patients will be followed by primary care team according to the usual health system routine.
Study NCT02768480 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone Calls Support and Primary Care
Description: Patients in intervention group will receive periodic phone calls (every three months) and will have a toll-free number to resolve questions about the disease management. The phone-calls will be performed by trained nurses and will follow a structured format. Nurses will address some topics: patient's treatment adherence, technique of insulin administration, disease understanding, hypoglycaemia management, healthy diet, smoke cessation and foot care.
Study NCT03869320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-1004-1239
Description: ACT-1004-1239 will be available for clinical study use as hard gelatin capsules for oral administration formulated in strengths of 1, 10, and 100 mg. For the ADME subpart, a single oral dose of 1 μCi of 14C radiolabeled ACT-1004-1239 will be given simultaneously with the ACT-1004-1239 capsule. For the absolute bioavailability subpart, a single intravenous dose of a maximum of 1 μCi of 14C radiolabeled ACT-1004-1239 will be given at the expected tmax after the administration of the ACT-1004-1239 capsule.
Study NCT03869320 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo is available as matching capsules for oral administration, formulated with the same excipients but without ACT-1004-1239.
Study NCT03869320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-1004-1239 (Food-effect subpart)
Description: ACT-1004-1239 will be available for clinical study use as hard gelatin capsules for oral administration formulated in strengths of 1, 10, and 100 mg.
Study NCT03869320 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Food-effect subpart)
Description: Matching placebo is available as matching capsules for oral administration, formulated with the same excipients but without ACT-1004-1239.
Study NCT03802825 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Self-Management Training
Description: The Decision-making Education for Choices in Diabetes Everyday (DECIDE) program is a nine-module, literacy adapted diabetes and cardiovascular disease education and problem-solving training program. Participants are taught the five steps of problem solving with each module going in depth on a single step: 1) identify the problem; 2) brainstorm possible strategies for problem resolution; 3) select the most appropriate strategy; 4) apply the strategy; 5) evaluate the effectiveness of the strategy. During the six months, CHWs will have weekly or bi-weekly contact with participants in-person or by phone to deliver the DECIDE modules and address social and economic needs.
Study NCT03802825 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Patient Navigation
Description: Once the participant has completed the YCLS assessment with study staff, the navigator will receive the referral and follow-up with the participant to address the social and economic needs identified. The patient navigator will follow-up with the participant 2-3 times over the 6 months by phone or in-person about progress with the referral and help address additional needs that may develop during the 6-month intervention.
Study NCT04249960 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Managed transition
Description: Young people, their family and clinicians will receive transition guidelines and will be asked to follow them as much as possible.
Study NCT02092298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Description: Mitomycin C 30 mg delivered laparoscopically for 60 minutes.
Study NCT02092298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 200 mg delivered laparoscopically 60 minutes, 2-8 weeks after completion of systemic chemotherapy.
Study NCT02092298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Thiosulfate
Description: Loading dose of 7.5 gm/M2 of Sodium Thiosulfate infused prior to addition of Cisplatin to the peritoneal perfusion circuit. Then a maintenance infusion of Sodium Thiosulfate 25.56 gm/M2 delivered by continuous infusion pump over 12 hours.
Study NCT01956773 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MeTree
Description: Software program collecting family health history and generating clinical decision support for risk-based preventive care
Study NCT01674881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy
Description: MBCT consists of 8 sessions, incl. 1 whole-day session, weekly meetings of app. 2 hours duration. Daily homework (app. 30-45 min).~Group format (app. 20 persons pr. group). Two trained instructors will manage the groups, both are MSc cand.psych, PhD.
Study NCT01674881 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist
Description: Waitlist: participants are offered the intervention (MBCT) after the completion of the main study
Study NCT01113372 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 75mg daily.
Study NCT01113372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel 75mg daily.
Study NCT01341288 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUCLIDIAN Robot
Description: EUCLIDIAN (Endo-Uro Computed Lattice for Intratumoral Delivery, Implantation, Ablation with Nanosensing) system for placement of radioactive seeds in the prostate
Study NCT02935712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8601+Placebo (SAD)
Description: Six subjects are randomized to receive one treatment of AZD8601 and one treatment of Placebo.~Single ascending dose (SAD) with a sequential cohort design and three dose levels of AZD8601 are planned to be investigated. Subjects will receive 0.004 mg per injection of AZD8601/placebo with a total proposed dose of 0.024 mg.
Study NCT02935712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8601+Placebo
Description: Subjects will receive dose with sufficient vascular endothelial growth factor (VEGF)-A protein production and a good safety profile as determined in Part A and the total dose per patient will not exceed the maximum dose given in Part A.
Study NCT02935712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo+Placebo
Description: Subjects are randomized to receive 2 placebo treatments.
Study NCT03976271 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp
Description: For this study, a hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp will be conducted to investigate the effect of hypoglycaemia. This means that subjects will receive an intravenous insulin infusion, at a continuous rate of 60 mU∙m-2∙min-1, as well as glucose 20% w/w intravenously at a variable rate, adjusted by arterial plasma glucose levels, measured at 5 minute intervals.
Study NCT03511105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2798745
Description: GSK2798745 will be available as white to slightly colored, round biconvex tablets to be administered via the oral route.
Study NCT03511105 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to GSK2798745 will be available as white to slightly colored, round biconvex tablet to be administered via the oral route.
Study NCT03511105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipoplysaccharide from Escherichia Coli
Description: LPS will be used as challenge agent. About 4 nanogram per kilogram of LPS will be instilled into the right middle lung segment via bronchoscopy 2 hours after dosing with GSK2798745 or placebo on Day 1.
Study NCT03511105 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lipoplysaccharide from Escherichia Coli
Description: LPS will be used as challenge agent. About 4 nanogram per kilogram of LPS will be instilled into the right middle lung segment via bronchoscopy 2 hours after dosing with GSK2798745 or placebo on Day 1.
Study NCT03511105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Sterile saline (0.9%) will be used as control challenge. Saline will be instilled into the lingula segment of contralateral side of lung via bronchoscopy 2 hours after dosing with GSK2798745 or placebo on Day 1.
Study NCT03511105 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Sterile saline (0.9%) will be used as control challenge. Saline will be instilled into the lingula segment of contralateral side of lung via bronchoscopy 2 hours after dosing with GSK2798745 or placebo on Day 1.
Study NCT02075203 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AERAS-404
Description: The H4 antigen is a fusion protein created from two Mtb antigens: antigen Ag85B and TB10.4. Ag85B is also referred to as α-antigen and is a 30-kDa mycolyl transferase protein. TB10.4 is one of three members of the very similar ESAT-6 group of proteins found in Mtb culture supernatants. TB10.4 induces broad immune responses in T cells isolated from TB subjects compared to BCG-vaccinated donors and unvaccinated donors. IC31 is a combination of a leucine-rich peptide named KLK \& a synthetic oligonucleotide named ODN1a. The optimal molar ratio of KLK to ODN1a in mice is 25:1. AERAS-404 \& saline placebo trial arms will be double-blinded since BCG causes a recognizable local injection site reaction, the BCG revaccination trial arm will be unblinded.
Study NCT02075203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study NCT02075203 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bacillus Calmette-Guérin (BCG)
Description: BCG SSI Vaccine is registered in South Africa for prevention of TB in children and adults. BCG, an attenuated, live culture of the Bacillus Calmette-Guérin, was originally attenuated between 1906 and 1919 by serial passage of an M. bovis strain. The manufacturer Statens Serum Institut (SSI) in Copenhagen, Denmark derives this vaccine from the Danish BCG strain 1331. BCG SSI is supplied by the manufacturer in amber 10-dose vials containing 0.75 mg lyophilized SSI BCG. The BCG revaccination trial arm will be unblinded (open label).
Study NCT03652051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZR-MD-001 Low Dose
Description: AZR-MD-001 is an ophthalmic ointment
Study NCT03652051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZR-MD-001 Mid Dose
Description: AZR-MD-001 is an ophthalmic ointment
Study NCT01136291 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: physical exercise
Description: The exercise protocol was done under supervision once a week. Pregnant women have been told to do some exercise three more times during the week unsupervised and may be the protocol of exercises or walk in mild to moderate intensity.~The exercise protocol lasted 50 minutes with 10 minutes of stretching overall, 30 minutes of exercise for muscle strengthening and 10 minutes of relaxation.~These women also received nutrition counseling and prenatal care.
Study NCT02696005 — intervention group
Intervention type: OTHER
Intervention: Exercise- Based Cardiac Rehabilitation Programme
Description: Exercise- Based Cardiac Rehabilitation Programme for patients suffering from Heart Failure.
Study NCT00499889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: 400 mg by mouth twice daily for 9 Days
Study NCT00499889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine (Fludara)
Description: 40 mg/m\^2 by vein daily for 4 Days
Study NCT00499889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 130 mg/m\^2 by vein daily for 2 Days
Study NCT00499889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithymocyte Globulin (ATG)
Description: 2.5 mg/kg by vein daily for 3 Days
Study NCT00499889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus levels maintained between 5-15 ng/dl, first as continuous IV infusion, and converted to oral every 12 hour dosing as tolerated. Starting day -2 until day 180.
Study NCT00499889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 5 mg/m2 on days 1, 3, 6 and 11.
Study NCT00499889 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Donor lymphocyte infusion (DLI)
Description: Infusion of lymphocytes from the original bone marrow donor by vein if relapse after >4 weeks of imatinib.
Study NCT00499889 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: Infusion of donor bone marrow or blood stem cells by vein over approximately one hour on day 0.
Study NCT04202159 — intervention group
Intervention type: DRUG
Intervention: Perampanel
Description: Perampanel tablets.
Study NCT04202159 — intervention group
Intervention type: DRUG
Intervention: Perampanel
Description: Perampanel oral suspension.
Study NCT01223664 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogenic bone marrow stem cells transplantation
Description: 30ml allogenic bone marrow stem cells were infused to patients using interventional method via portal vein or hepatic artery as well as conserved therapy
Study NCT01223664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conserved therapy
Description: Oral or intravenous administration
Study NCT02319239 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Fractionation
Description: During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 15/39 fractions. DW-MRI at baseline, 3 months and 12 months.
Study NCT02319239 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated
Description: During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 10/20 fractions. DW-MRI at baseline, 3 months and 12 months